{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=48", "query": { "intervention": "Combination Agent", "page": 48 }, "page_size": 10 }, "pagination": { "page": 48, "page_size": 10, "total_count": 5568, "total_pages": 557, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=49&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=47&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T19:11:10.016Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01476475", "title": "Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine /lixisenatide Fixed Ratio Combination", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Metformin (Background drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 323, "start_date": "2011-11", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2017-02-10", "last_synced_at": "2026-11-15T19:11:10.016Z", "location_count": 14, "location_summary": "Little Rock, Arkansas • Paramount, California • Larenceville, Georgia + 11 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Paramount", "state": "California" }, { "city": "Larenceville", "state": "Georgia" }, { "city": "Roswell", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01476475" }, { "nct_id": "NCT00000972", "title": "A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "HIV Seronegativity" ], "interventions": [ { "name": "MTP-PE/MF59", "type": "BIOLOGICAL" }, { "name": "Env 2-3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 64, "start_date": null, "completion_date": "1992-04", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-11-15T19:11:10.016Z", "location_count": 3, "location_summary": "Rochester, New York • Nashville, Tennessee • Seattle, Washington", "locations": [ { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000972" }, { "nct_id": "NCT00408005", "title": "Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "T Acute Lymphoblastic Leukemia", "T Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Asparaginase", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 1895, "start_date": "2007-01-30", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-11-15T19:11:10.016Z", "location_count": 191, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00408005" }, { "nct_id": "NCT07389239", "title": "A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Advanced Malignant Solid Tumor" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Cyclophosphamide Conditioning", "type": "DRUG" }, { "name": "NY-ESO-1 TCR/ dnTGFβRII", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-09-09", "completion_date": "2031-12-10", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-15T19:11:10.016Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07389239" }, { "nct_id": "NCT00857766", "title": "A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "ADVAIR DISKUS™ 250/50mcg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 249, "start_date": "2009-03", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-11-15T19:11:10.016Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00857766" }, { "nct_id": "NCT06065722", "title": "Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chemotherapy Induced Nausea and Vomiting" ], "interventions": [ { "name": "Akynzeo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Simon Williamson Clinic", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2023-09-09", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-11-15T19:11:10.016Z", "location_count": 1, "location_summary": "Mount Olive, Alabama", "locations": [ { "city": "Mount Olive", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06065722" }, { "nct_id": "NCT03960645", "title": "Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "FEMALE", "summary": "18 Years to 39 Years · Female only" }, "enrollment_count": 62, "start_date": "2019-06-28", "completion_date": "2022-08-18", "has_results": true, "last_update_posted_date": "2024-06-14", "last_synced_at": "2026-11-15T19:11:10.016Z", "location_count": 2, "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03960645" }, { "nct_id": "NCT01095757", "title": "Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloma", "Lymphoma" ], "interventions": [ { "name": "Plerixafor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 45, "start_date": "2010-03", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2014-09-29", "last_synced_at": "2026-11-15T19:11:10.016Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01095757" }, { "nct_id": "NCT01061788", "title": "A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors, Non-small Cell Lung Cancer" ], "interventions": [ { "name": "AMG 479, Everolimus, Panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeffrey Clarke", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 43, "start_date": "2010-04", "completion_date": "2018-12-19", "has_results": false, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-11-15T19:11:10.016Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01061788" }, { "nct_id": "NCT00000661", "title": "The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Oxazepam", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2008-08-04", "last_synced_at": "2026-11-15T19:11:10.016Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000661" } ] }